CAR-T Cell Therapy Market (53% CAGR) To 2025: Global Industry Size, Share, Growth, Trends and Forecast

According to a new market research report published by sheer analytics and insights, “The Global CAR-T Cell therapy market in terms of revenue is expected to grow at a CAGR of 53% from 2018 to 2025” as per market research report titled Global CAR-T Cell Therapy Market (By Targeted Antigen – HER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO and EGFRVIII, By Treatment – Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Lymphoblastic Leukemia(ALL), Multiple Myeloma, Acute Myeloid Leukemia(AML), Breast Cancer, Pancreatic Cancer, Neuroblastoma (NB), Colon Cancer and Hepatocellular Carcinoma (HCC)) – Global Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2017 – 2025.

For many years, the foundations for cancer treatment has been chemotherapy, radiation therapy, and surgery. Over the past several years immunotherapy has emerged that enlist and strengthen the power of the patient’s immune system so that they can attack tumors. It is now also known as the “fifth pillar” of cancer treatment. However, recently researchers have come up with a more advanced treatment for cancer, known as, CAR-T Cell therapy.

Browse Full report at https://www.sheeranalyticsandinsights.com/market-report-research/car-t-cell-therapy-market-21

What is this CAR-T Cell therapy?

CAR-T Cell therapy is a variation of immunotherapy popularly known as the adoptive cell therapy. The T cells are the type of white blood cell that is extracted by the doctor from the patient’s blood and then they add an artificial receptor to their surface. The receptor acts as a type of “heat-seeking missile” and this enables the modified cells to produce a type of chemicals that can kill cancer. Once they are infused back into the patient’s body through an IV, they start multiplying and attack tumor cells.

 The CAR-T cell is a type of antibody that induces modular-fusion protein having an extracellular specific binding domain. This therapy has made it possible to provide treatment against recurrence option for blood cancer and other carcinogenic cases. Needless to say, today CAR-T cell in the carcinogenic therapeutics field has become a boon to the healthcare industry. Owing to this factor many companies have started investing in the CAR-T cell therapy which has increased its market and continues to do so. Presently, the most successful is the CD 19 antigen which is used for treating acute lymphoblastic leukemia (ALL). The Food and Drug Administration (FDA) has also approved the first genetic engineering which is based on Kymriah (tisagenlecleucel) by Novartis AG. Moreover, there are also other various clinical trials on the process by using the CAR-T cell therapy which can combat another kind of tumors and acute myeloid leukemia.

 The major reason behind the rapid growth of the CAR-T cell therapy market is because of the intensified growth of cancer cases. Furthermore, the technological advancement in this field is also contributing and creating a huge potential for the growth of the market. However, the high price of the therapy packages and the longer period of their clinical trials is proving to be a barrier for the growth of the CAR-T cell market. As per market research, no more than 150 patients will be getting this treatment in 2018.

 As per the segmentation of the regions in the report, the CAR-T cell therapy market is segmented into North America, Latin America, Europe, Middle East & Africa, and the Asia Pacific. However, the market is dominated by North America and Europe. The demand of CAR-T cell therapy is increasing in this region owing to the rising prevalence of disease, growing awareness among the people, the increase in geriatric population, and world-class diagnosis techniques. It is estimated that the market in the region of Asia Pacific will also increase during the forecasted period. The market over here is mainly driven by the rising awareness regarding cancer, advanced diagnosis laboratories, and the initiatives that are taken by the government spread awareness among the people.

 In the aforementioned market research report published by Sheer Analytics and Pvt. Ltd. the global CAR T cell therapy market has been categorized on the basis of targeted antigen, treatment and by geographical boundaries.

 The targeted segment includes– HER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO, and EGFRvIII; the CD19 section is predicted to grab the major share of the global CAR-T cell therapy market due to its highest success rate in detecting and treating acute lymphoblastic leukemia (ALL). Treatment type segment includes non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), multiple myeloma, acute myeloid leukemia (AML), breast cancer, pancreatic cancer, neuroblastoma (NB), colon cancer and hepatocellular carcinoma (HCC). Here, the acute lymphoblastic leukemia group is dominating the other diseases.

 Ceyland, a clinical biopharmaceutical company has focused on the development of CAR-T cell therapies, and they have announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for CYAD-101. This will be the first non-gene edited allogenic clinical program.

 The CEO of Ceylad, Dr. Christian Homsy told: “We are pleased to have achieved this important milestone. Celyad is the first company clinically evaluating a non-gene edited CAR-T candidate, which, we believe, offers significant advantages over gene edited approaches. Our non-gene edited program consists of a family of technologies aimed at reducing or eliminating T cell receptor (TCR) signaling without requiring genetic manipulation. CYAD-101 is part of a robust clinical development plan, establishing the foundations of next-generation CAR-T products.”

List of Companies Covered:

  • Novartis International AG,
  • Kite Pharma Inc.,
  • Juno Therapeutics,
  • Cellectis, Bellicum Pharmaceuticals Inc. and
  • Celgene Corporation
  • among others.

Global CAR-T Cell Therapy Market and its segmentation:

By Targeted Antigen Type

  • HER1
  • HER2
  • CD19
  • CD20
  • CD22
  • CD30
  • CD33
  • GD2
  • MESO and
  • EGFRvIII

By Treatment Type

  • Non-Hodgkin lymphoma (NHL)
  • Chronic lymphocytic leukemia (CLL)
  • Acute lymphoblastic leukemia (ALL)
  • Multiple myeloma
  • Acute myeloid leukemia (AML)
  • Breast cancer
  • Pancreatic cancer
  • Neuroblastoma (NB)
  • Colon cancer and
  • Hepatocellular carcinoma (HCC) 

By Geography Type

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

To know more about this study, request a free sample report @ https://www.sheeranalyticsandinsights.com/request-sample/car-t-cell-therapy-market-21

About Us:

Sheer Analytics and Insights as firm is created to balance between client requirements without compromising the core values of Market research in –terms of quality, factual correctness, market awareness and analysis. SAI goes back to the root of Market Research in terms of TAM (Total Available Market) and PAM (Potential Available Market) and assess the same quantifying all Push and Pull factors.

Contact us:

Name: Abhigyan Sengupta

(Global sales Manager)

Ph.: +1-414-240-5010 (U.S.)

RDB Boulevard, 8th Floor,

Plot K 1, Sector 5, Block EP and GP,

Kolkata 700091, India.

Email: sales@sheeranalyticsandinsights.com

Website: https://www.sheeranalyticsandinsights.com/

2 Replies to “CAR-T Cell Therapy Market (53% CAGR) To 2025: Global Industry Size, Share, Growth, Trends and Forecast”

Leave a Reply

Your email address will not be published. Required fields are marked *